Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) (original) (raw)

Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) A.F. Hernandez1, M.A. Bethel2, G.L. Bakris3, P. Merrill1, S.M. Gustavson4, B.G. Katona4, P. Ohman4, Y. Lokhnygina1, R.J. Mentz1, R.R. Holman2, for the EXSCEL Study Group; 1Duke Clinical Research Institute, Durham, USA, 2Diabetes Trials Unit, Oxford, UK, 3University of Chicago Medicine, Chicago, USA, 4AstraZeneca, Gaithersburg, USA.